Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolites of [14C]-5-(2-Ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine in Mice, Rats, Dogs, and Humans

Ellen Bech Christensen, Jan Bruun Andersen, Henrik Pedersen, Klaus Gjervig Jensen and Lars Dalgaard
Drug Metabolism and Disposition November 1999, 27 (11) 1341-1349;
Ellen Bech Christensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Bruun Andersen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Pedersen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Gjervig Jensen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Dalgaard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The M1 muscarine agonist, 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine (Lu 25–109), is extensively metabolized in mice, rats, dogs, and humans. The metabolite profile after an oral dose of [14C]Lu 25–109 was determined in plasma and in urine. Lu 25–109 was metabolized by N-demethylation (Lu 25–077),N-oxidation (Lu 32–181), andN-deethylation (Lu 31–126). In addition, combinedN-demethylation and N-deethylation (Lu 31–190), and formation of a pyridine derivative took place (Lu 31–102). Lu 25–109 was also oxidized to pyridinium (Lu 29–297), 3-hydroxy-pyridinium (Lu 35–080), N-deethyl-2-pyridone (Lu 35–026), and a glucuronide of a 4,6-dihydroxy-pyridinium (“m/z 398”) compounds. A glucuronide of a dihydroxylated dihydro-pyridine compound (“m/z 400”) was isolated from human urine, but not fully identified. In vitro studies were undertaken to elucidate the order of formation of the metabolites. In human plasma, the concentrations of Lu 25–109 and the pharmacologically activeN-demethyl metabolite (Lu 25–077) were small compared with the N-oxide (Lu 32–181) and theN-deethyl-2-pyridone (Lu 35–026) at the first sample time (0.75 h). The N-deethyl metabolite (Lu 31–126) was the major component in human plasma between 3 and 10 h postdose. The major human metabolites in urine (Lu 32–181, Lu 35–026, and Lu 31–126) and the minor metabolites (Lu 25–077, Lu 35–080, Lu 31–190, and Lu 29–297) were all present in urine from rats, dogs, and mice, whereas m/z 398 was present in only mice and humans, and Lu 31–102 in only rats. The minor human metabolite m/z 400 was not detected in mice, rats, or dogs.

Footnotes

  • Send reprint requests to: Dr. Ellen Bech Christensen, Department of Drug Metabolism, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen-Valby, Denmark. E-mail: ebc{at}lundbeck.com

  • Abbreviations used are::
    HMBC
    heteronucleous multiple bond correlation
    LSC
    liquid scintillation counting
    LC/MS
    liquid chromatography/mass spectrometry
    NOE
    nuclear Overhauser enhancement
    • Received December 11, 1998.
    • Accepted August 2, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (11)
Drug Metabolism and Disposition
Vol. 27, Issue 11
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolites of [14C]-5-(2-Ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine in Mice, Rats, Dogs, and Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolites of [14C]-5-(2-Ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine in Mice, Rats, Dogs, and Humans

Ellen Bech Christensen, Jan Bruun Andersen, Henrik Pedersen, Klaus Gjervig Jensen and Lars Dalgaard
Drug Metabolism and Disposition November 1, 1999, 27 (11) 1341-1349;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolites of [14C]-5-(2-Ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine in Mice, Rats, Dogs, and Humans

Ellen Bech Christensen, Jan Bruun Andersen, Henrik Pedersen, Klaus Gjervig Jensen and Lars Dalgaard
Drug Metabolism and Disposition November 1, 1999, 27 (11) 1341-1349;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
  • Biotransformation of Trastuzumab and Pertuzumab
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics